Glycomics in Canada receives crucial funding boost to further life-saving research and biotechnology development.
Researchers are a step closer to understanding how Parkinson’s disease develops and progresses.
Glycomics is an integral part of ABOzymes’ life-saving research and technology development.
Read some highlights from the 2022 Canadian Glycomics Symposium.
Findings show promise for developing potential new anti-inflammatory drugs and treatments for autoimmune diseases.
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.
In BIOTECanada’s Insights Magazine, GlycoNet Scientific Director Warren Wakarchuk writes about the importance of glycomics, opportunities to leverage glycomics, and Canadian glycomics expertise.
Linkedin-in Twitter Facebook-f Instagram Youtube Envelope
This investment will support state-of-the-art health research for Canada’s leading diseases, including cancer, diabetes, dementia, muscular dystrophy and universal donor blood.
GlycoNet researchers are studying a group of molecules that could provide insight into treating and monitoring neurodegenerative diseases.